CROSSJECT Stock Euronext Paris
Stocks
FR0011716265
Medical Equipment, Supplies & Distribution
OTC Markets Traded|
End-of-day quote
Euronext Paris
|
||
| - EUR | - |
|
| 09-24 | CROSSJECT Aligns ZEPIZURE Pediatric Development Plan With BARDA And FDA | CI |
| 05-26 | Crossject: The last round of financing? | AL |
| Market Cap | 72.41M 82.32M 68.26M 62.28M 116M 7.9B 117M 819M 317M 4.02B 309M 302M 13.09B | P/E 2026 * |
3.24x | P/E 2027 * | 2.56x |
|---|---|---|---|---|---|
| Enterprise Value | 54.51M 61.97M 51.39M 46.88M 87.68M 5.95B 88.36M 617M 239M 3.03B 233M 228M 9.85B | EV / Sales 2026 * |
0.9x | EV / Sales 2027 * | 0.39x |
| Free-Float |
92.46% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 08/08/2001 | |
Lionel Seltz
DFI | Director of Finance/CFO | - | 25/03/2026 |
Tony C. Tipton
PRN | Corporate Officer/Principal | - | 20/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Philippe Monnot
CHM | Chairman | 67 | 26/06/2009 |
Eric Nemeth
BRD | Director/Board Member | 67 | - |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.82% | +1.37% | +163.56% | +454.21% | 106M | |
| -1.81% | -5.15% | -24.50% | -46.61% | 99.74M | |
| +1.37% | +0.91% | -19.69% | -65.45% | 81.38M | |
| +3.07% | -2.89% | +40.00% | +26.32% | 73.56M | |
| Average | +2.61% | -1.32% | +39.84% | +92.11% | 90.18M | |
| Weighted average by Cap. | +2.73% | -1.88% | +45.02% | +111.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 60.8M 69.12M 57.32M 52.29M 97.79M 6.64B 98.55M 688M 267M 3.38B 260M 254M 10.99B | 65.2M 74.12M 61.46M 56.08M 105M 7.12B 106M 738M 286M 3.62B 278M 272M 11.78B |
| Net income | 28.3M 32.17M 26.68M 24.34M 45.52M 3.09B 45.87M 320M 124M 1.57B 121M 118M 5.11B | 35.6M 40.47M 33.56M 30.62M 57.26M 3.89B 57.71M 403M 156M 1.98B 152M 149M 6.43B |
| Net Debt | -17.9M -20.35M -16.87M -15.4M -28.79M -1.95B -29.02M -202M -78.47M -994M -76.41M -74.75M -3.24B | -47M -53.43M -44.31M -40.42M -75.6M -5.13B -76.19M -532M -206M -2.61B -201M -196M -8.49B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
